- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02355015
A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections
The study aims to address the following aims
- To provide an overview of the epidemiology of the patients who are managed in the Singapore General Hospital for NTM infections.
- To evaluate the medical care of patients in the institution with regards to the type of medical and/or surgical treatment received and specifically, the antibiotic regime and duration administered.
- A longitudinal follow up which will allow an assessment of our care and patient outcome in this population cohort
Study Overview
Status
Conditions
Detailed Description
Nontuberculous Mycobacteria (NTM) is difficult to treat and has no standardised antibiotic therapy. There have been increasing recognition of the need for measurements of NTM care around the world, as rates of NTM infections have begun to supercede Tuberculosis infections for the first time. As health care-associated NTM outbreaks also pose an infection control risk for patients undergoing surgery, this study provides a platform for further greater uniformity and opportunities for improvement in care. (1,2)
Singapore General Hospital (SGH) is a tertiary hospital and sees patients of various complex medical illnesses. Patients with Nontuberculous Mycobacteria (NTM) infections are also on follow up with the infectious diseases specialists SGH. The care of NTM patients can last many years, with patients requiring multiple admissions for reinfections/relapses and are often on long term suppressive therapy and follow up at the Specialist Outpatient Clinic. (3,4)The lack of standardised care for NTM patients, lengthy treatment time for NTM infections, as well as increases in macrolide-resistant NTM infections, warrants a need for research into the epidemiology and best practice to treat this group of patients. (5,6) We seek to better define the epidemiology of this group of patients and hope to objectively measure the effectiveness and quality of our NTM care delivery in SGH.
Currently there is a lack of a systematic database to track our quality of care and support services. As there are many Infectious Diseases Specialists in the department, each may have slight variation in clinical practice and preference in the face of a lack of proper treatment guideline. We believe NTM management can be improved with a consistent care delivery pathway and more standardization of therapy and follow up plan. This will lead to better desired patient outcome. This prospective observational data collection will allow us to evaluate our current standard of care for these patients, which can lead to identification for areas of improvement so that we can refine our strategies and implement more effective and standardized guidelines in the future.
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med 2007; Feb 15;175(4):367-416
- Cook JL. Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts. Br Med Bull 2010;96:45-59
- Piersimoni C. Nontuberculous mycobacteria infection in solid organ transplant recipients. European Journal of Clinical Microbiology & Infectious Diseases 2012 Apr;31(4):397-403
- Payen MC, De Wit S, Clumeck N. Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection. Revue des Maladies Respiratoires 1997 Dec;14 Suppl 5:S142-51
- Russell CD, Claxton P, Doig C, Seagar AL, Rayner A, Laurenson IF. Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax 2013 [Epub ahead of print]
- Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of Nontuberculous Mycobacterial Infections and Associated Chronic Macrolide Use among Persons with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine 2013; [Epub ahead of print]
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Benjamin Cherng
- Phone Number: 63213479
- Email: benjamin.cherng.p.z@sgh.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169856
- Recruiting
- Singapore General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients diagnosed with Nontuberculous Mycobacteria infections.
Exclusion Criteria:
- Patient refusal to participate in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: 5 years
|
Patients will be followed up on an outpatient basis and mortality outcomes (all cause) at 6 months, 1 year and 5 years will be monitored.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response
Time Frame: 6 months from start of treatment
|
Managing clinician will judge the clinical response post-induction and post-maintenance treatment.
Responses classified as resolved, improved, stable or worse.
|
6 months from start of treatment
|
Microbiological response
Time Frame: 6 months from start of treatment
|
This is specifically for NTM infections involving the lung.
Sputum samples will be collected regularly in the 6 month period to document clearance of NTM growth from the sputum.
A microbiological response would be classified as 2-3 negative consecutive sputum cultures in the 6 month period.
|
6 months from start of treatment
|
Chest Xray changes
Time Frame: 6 months
|
This is specifically for NTM infections involving the lung.
Chest Xray post completion of treatment will be assess and classified as resolved, improved, stable or worse.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benjamin Dr Cherng, MBBS, Singapore General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/205/F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mycobacterium Infections, Nontuberculous
-
Kevin WinthropPatient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaboratorsRecruitingMycobacterium Avium Complex | Nontuberculous Mycobacterium InfectionUnited States, Canada
-
The University of Texas Health Science Center at...AbbottCompletedMycobacterium Avium Complex | Nontuberculous MycobacteriaUnited States
-
University of Illinois at ChicagoTerminatedAtypical Mycobacterium Infections | Nontuberculous Mycobacterial DiseaseUnited States
-
Inje UniversityMinistry of Science and ICTRecruitingLatent Tuberculosis | Tuberculosis | Nontuberculous Mycobacterium InfectionKorea, Republic of, Indonesia
-
The University of Texas Health Science Center at...PfizerCompletedNontuberculous Mycobacterial InfectionsUnited States
-
Oregon Health and Science UniversityUniversity Health Network, Toronto; New York University; NTM Info & Research,...RecruitingNontuberculous Mycobacterial Lung Disease | Nontuberculous Mycobacterium InfectionUnited States, Canada
-
LigaChem Biosciences, Inc.Active, not recruitingMycobacterium Abscessus Infection | Nontuberculous Mycobacterium InfectionKorea, Republic of
-
Paratek Pharmaceuticals IncActive, not recruitingMycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary InfectionUnited States
-
Radboud University Medical CenterRecruitingNontuberculous Mycobacterial Lung Disease | Mycobacterium Avium ComplexNetherlands
-
Seoul National University HospitalUnknownWhole Genome Sequencing | Nontuberculous Mycobacterium InfectionKorea, Republic of